Business Wire

MA-OPTIKOS

12.9.2022 20:32:37 CEST | Business Wire | Press release

Share
Optikos Announces New Optical Testing Products to Meet Automotive Imaging Demands

Optikos Corporation introduced three new products to its OpTest® and Meridian® lens and camera metrology product lines, developed to address the specific requirements for testing and image capture conditions in the field of automotive imaging.

Optikos has a long history of pioneering the development and commercialization of test equipment for the evaluation of lenses and cameras, including the OpTest® and LensCheck product families, widely regarded as the gold standard for assessing the image quality of lens assemblies; and the Meridian product line, for measuring the performance of an assembled camera. The Company is recognized not only for its comprehensive range of standard products, but also its readiness to customize hardware and software to suit a customer’s particular requirements such as those demanded in automotive imaging applications.

With two of its newest products, Optikos has extended its expertise in measuring the effects of stray light in lenses to camera assemblies—with the Meridian camera testing line now including products that serve as sources for measuring Veiling Glare Index (VGI) and Glare Spread Function (GSF).

VGI measurements are useful as a measure of diffuse irradiance on the image plane, and require a uniformly illuminated background field populated with one or more dark objects. The new Meridian VGI source is a customizable hemispherical integrating sphere into which light traps of various sizes may be fitted; and enables the customer to specify the sizes and locations of the light traps according to the characteristics of the camera assemblies to be tested. The system is illuminated using white LEDs, the intensity of which may be remotely controlled.

Glare Spread Function testing evaluates the severity of ghost reflections or other prominent stray light artifacts that form concentrated irradiation patterns. The new Meridian Sol-55 projector addresses this need with a modular design, and features interchangeable object aperture drawers for controlling the angular extent of the projected target, and an aperture wheel that controls the numerical aperture of the illumination through the object aperture. “The unique design avoids overfilling the lens under test and creating a secondary source of stray light from adjacent scattering surfaces; while illumination is provided by a high intensity white LED which can be remotely controlled for high dynamic range measurements,” said David Imrie, Optikos Chief Technology Officer.

Meridian Sol-55 projectors are designed to be flexibly mounted at pre-determined field points with respect to the device-under-test in rigid assemblies that form a Meridian Sunfield system. They are distinguished from Meridian Starfield assemblies of Static Target Projectors (STPs) used in image quality (MTF) testing of cameras.

In addition to stray light, temperature extremes pose a significant challenge for image sensor performance in automotive cameras. Optikos has been testing lenses across a range of temperatures in its IQ Lab™ Optical Testing Service since 2017, and first productized this process for testing lenses up to 150mm with its Thermal Module TM-1150 system.

The new TC-1065 is a thermal chamber used for lens testing that extends the maximum size of lenses that may be tested over a range of temperatures on a LensCheck system, complementing the smaller TC-1050 and TC-1010 products also available in the product line. In order to optimize the thermal performance, the thermal chamber is generally sized to match the dimensions of the lenses with which it will be used.

Optikos will be exhibiting at AutoSens Brussels 2022 on October 12-14th. To learn more about Optikos solutions for automotive imaging, see contact details below.

About Optikos

The Optical Engineering Experts®—Optikos provides leading-edge applications of optical technology to organizations worldwide. For customers who require optical testing and image quality assessment of lens and camera systems, we offer an advanced line of standard and custom metrology products as well as in-house IQ Lab™ Optical Testing Services. We offer product development services that include a broad range of engineering, contract manufacturing, and assembly capabilities. Our broad skill set, including optics, mechanics, electronics, automation, and software systems, enables us to quickly understand our customers' unique technical requirements and provide a flexible and scalable resource. Applications range from medical devices and diagnostics to aerial imaging, defense, automotive cameras, and well beyond.

For more information, visit optikos.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005764/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye